{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:06:24Z","timestamp":1779149184069,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T00:00:00Z","timestamp":1434412800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s11095-015-1738-7","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T17:07:11Z","timestamp":1434388031000},"page":"3768-3781","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention"],"prefix":"10.1007","volume":"32","author":[{"given":"Charlene S.","family":"Dezzutti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Yandura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Moncla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Teeple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brid","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Nuttall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa C.","family":"Rohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,16]]},"reference":[{"issue":"6122","key":"1738_CR1","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1126\/science.1228160","volume":"339","author":"F Tanser","year":"2013","unstructured":"Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339(6122):966\u201371.","journal-title":"Science"},{"issue":"9","key":"1738_CR2","doi-asserted-by":"crossref","first-page":"e1001509","DOI":"10.1371\/journal.pmed.1001509","volume":"10","author":"B Auvert","year":"2013","unstructured":"Auvert B, Taljaard D, Rech D, Lissouba P, Singh B, Bouscaillou J, et al. Association of the ANRS-12126 male circumcision project with HIV levels among Men in a South African township: evaluation of effectiveness using cross-sectional surveys. PLoS Med. 2013;10(9):e1001509.","journal-title":"PLoS Med"},{"key":"1738_CR3","first-page":"CD003510","volume":"7","author":"N Siegfried","year":"2011","unstructured":"Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011;7:CD003510.","journal-title":"Cochrane Database Syst Rev"},{"key":"1738_CR4","unstructured":"(UNAIDS) JUNPoHA. Global report: UNAIDS report on the global AIDS epidemic 2013. UNAIDS. Available from: http:\/\/www.unaids.org\/en\/media\/unaids\/contentassets\/documents\/epidemiology\/2013\/gr2013\/UNAIDS_Global_Report_2013_en.pdf ."},{"issue":"5","key":"1738_CR5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410.","journal-title":"N Engl J Med"},{"issue":"5","key":"1738_CR6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423\u201334.","journal-title":"N Engl J Med"},{"issue":"5","key":"1738_CR7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","volume":"367","author":"L Damme Van","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"6","key":"1738_CR8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","volume":"372","author":"JM Marrazzo","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509\u201318.","journal-title":"N Engl J Med"},{"issue":"5996","key":"1738_CR9","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","volume":"329","author":"Q Abdool Karim","year":"2010","unstructured":"Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168\u201374.","journal-title":"Science"},{"issue":"7","key":"1738_CR10","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/QAD.0b013e32834541d9","volume":"25","author":"SS Abdool Karim","year":"2011","unstructured":"Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25(7):957\u201366.","journal-title":"AIDS"},{"issue":"9654","key":"1738_CR11","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/S0140-6736(08)61842-5","volume":"372","author":"S Skoler-Karpoff","year":"2008","unstructured":"Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977\u201387.","journal-title":"Lancet"},{"issue":"5","key":"1738_CR12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1056\/NEJMoa0707957","volume":"359","author":"L Damme Van","year":"2008","unstructured":"Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359(5):463\u201372.","journal-title":"N Engl J Med"},{"key":"1738_CR13","unstructured":"Rees H, S A D-M, Lombard C, Baron D, Panchia R, Myer L, Schwartz JL, Doncel GF, Gray G. FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women. In.Conference on Retroviruses and Opportunistic Infections. Seattle, WA; 2015."},{"issue":"1","key":"1738_CR14","doi-asserted-by":"crossref","first-page":"e55013","DOI":"10.1371\/journal.pone.0055013","volume":"8","author":"CW Hendrix","year":"2013","unstructured":"Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One. 2013;8(1):e55013.","journal-title":"PLoS One"},{"issue":"9787","key":"1738_CR15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0140-6736(11)60878-7","volume":"378","author":"SS Karim","year":"2011","unstructured":"Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378(9787):279\u201381.","journal-title":"Lancet"},{"issue":"2","key":"1738_CR16","doi-asserted-by":"crossref","first-page":"e9310","DOI":"10.1371\/journal.pone.0009310","volume":"5","author":"LC Rohan","year":"2010","unstructured":"Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, Gai F, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One. 2010;5(2):e9310.","journal-title":"PLoS One"},{"issue":"2","key":"1738_CR17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAI.0b013e3181e3293a","volume":"55","author":"AM Nel","year":"2010","unstructured":"Nel AM, Smythe SC, Habibi S, Kaptur PE, Romano JW. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr. 2010;55(2):161\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"1738_CR18","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","volume":"46","author":"X Wei","year":"2002","unstructured":"Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46(6):1896\u2013905.","journal-title":"Antimicrob Agents Chemother"},{"key":"1738_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27\u201355.","journal-title":"Adv Enzym Regul"},{"issue":"2","key":"1738_CR20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/AAC.01156-08","volume":"53","author":"P Fletcher","year":"2009","unstructured":"Fletcher P, Harman S, Azijn H, Armanasco N, Manlow P, Perumal D, et al. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2009;53(2):487\u201395.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1738_CR21","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","volume":"49","author":"P Dorr","year":"2005","unstructured":"Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49(11):4721\u201332.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1738_CR22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11904-012-0148-2","volume":"10","author":"CS Dezzutti","year":"2013","unstructured":"Dezzutti CS, Hladik F. Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities. Curr HIV\/AIDS Rep. 2013;10(1):12\u201320.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"1","key":"1738_CR23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/QCO.0b013e32834ef5c4","volume":"25","author":"S Lucas","year":"2012","unstructured":"Lucas S. Causes of death in the HAART era. Curr Opin Infect Dis. 2012;25(1):36\u201341.","journal-title":"Curr Opin Infect Dis"},{"issue":"16","key":"1738_CR24","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/QAD.0b013e32834b3629","volume":"25","author":"C Herrera","year":"2011","unstructured":"Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants. AIDS. 2011;25(16):1971\u20139.","journal-title":"AIDS"},{"issue":"13","key":"1738_CR25","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1097\/QAD.0b013e3283491f89","volume":"25","author":"SM Schader","year":"2011","unstructured":"Schader SM, Colby-Germinario SP, Schachter JR, Xu H, Wainberg MA. Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination. AIDS. 2011;25(13):1585\u201394.","journal-title":"AIDS"},{"issue":"4","key":"1738_CR26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/QAI.0000000000000472","volume":"68","author":"MR Nicol","year":"2015","unstructured":"Nicol MR, Emerson CW, Prince HM, Nelson JA, Fedoriw Y, Sykes C, et al. Models for predicting effective HIV chemoprevention in women. J Acquir Immune Defic Syndr. 2015;68(4):369\u201376.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"1738_CR27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/AAC.48.1.337-339.2004","volume":"48","author":"Y Herrewege Van","year":"2004","unstructured":"Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, Balzarini J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother. 2004;48(1):337\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1738_CR28","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/aid.2009.0227","volume":"26","author":"AM Nel","year":"2010","unstructured":"Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, Kaptur PE, et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retrovir. 2010;26(11):1181\u201390.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"7","key":"1738_CR29","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.bcp.2013.08.013","volume":"86","author":"EE To","year":"2013","unstructured":"To EE, Hendrix CW, Bumpus NN. Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues. Biochem Pharmacol. 2013;86(7):979\u201390.","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"1738_CR30","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/infdis\/jir059","volume":"203","author":"KC Brown","year":"2011","unstructured":"Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HM, Dumond JB, et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis. 2011;203(10):1484\u201390.","journal-title":"J Infect Dis"},{"issue":"5","key":"1738_CR31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/QAI.0b013e3181ae69c5","volume":"51","author":"JB Dumond","year":"2009","unstructured":"Dumond JB, Patterson KB, Pecha AL, Werner RE, Andrews E, Damle B, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr. 2009;51(5):546\u201353.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"16","key":"1738_CR32","doi-asserted-by":"crossref","first-page":"8952","DOI":"10.1128\/JVI.01204-13","volume":"87","author":"I Massud","year":"2013","unstructured":"Massud I, Aung W, Martin A, Bachman S, Mitchell J, Aubert R, et al. Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. J Virol. 2013;87(16):8952\u201361.","journal-title":"J Virol"},{"issue":"1\u20132","key":"1738_CR33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bcp.2005.10.024","volume":"71","author":"C Napier","year":"2005","unstructured":"Napier C, Sale H, Mosley M, Rickett G, Dorr P, Mansfield R, et al. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005;71(1\u20132):163\u201372.","journal-title":"Biochem Pharmacol"},{"key":"1738_CR34","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/jcph.248","volume":"54","author":"MR Nicol","year":"2014","unstructured":"Nicol MR, Fedoriw Y, Mathews M, Prince HM, Patterson KB, Geller E, et al. Expression of six drug transporters in vaginal, cervical, and colorectal tissues: implications for drug disposition in HIV prevention. J Clin Pharmacol. 2014;54:574\u201383.","journal-title":"J Clin Pharmacol"},{"key":"1738_CR35","doi-asserted-by":"crossref","unstructured":"Dobard C, Taylor A, Sharma S, Chuong D, Pau CP, Rohan L, McGowan I, Heneine W. Rectal Specific Gels Containing Maraviroc and\/or Tenofovir Protect against Rectal SHIV Transmission in a Macaque Model. In.HIV Research for Prevention. Cape Town, SA; 2014. p. 45.","DOI":"10.1089\/aid.2014.5013a.abstract"},{"issue":"3","key":"1738_CR36","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jac\/dks422","volume":"68","author":"RK Malcolm","year":"2013","unstructured":"Malcolm RK, Forbes CJ, Geer L, Veazey RS, Goldman L, Klasse PJ, et al. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother. 2013;68(3):678\u201383.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1738_CR37","doi-asserted-by":"crossref","first-page":"e77340","DOI":"10.1371\/journal.pone.0077340","volume":"8","author":"M Gunawardana","year":"2013","unstructured":"Gunawardana M, Mullen M, Moss JA, Pyles RB, Nusbaum RJ, Patel J, et al. Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis. PLoS One. 2013;8(10):e77340.","journal-title":"PLoS One"},{"issue":"9","key":"1738_CR38","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1086\/462424","volume":"192","author":"SR Abner","year":"2005","unstructured":"Abner SR, Guenthner PC, Guarner J, Hancock KA, Cummins Jr JE, Fink A, et al. A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis. 2005;192(9):1545\u201356.","journal-title":"J Infect Dis"},{"issue":"5","key":"1738_CR39","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1128\/AAC.01129-06","volume":"51","author":"JE Cummins Jr","year":"2007","unstructured":"Cummins Jr JE, Guarner J, Flowers L, Guenthner PC, Bartlett J, Morken T, et al. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother. 2007;51(5):1770\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1738_CR40","doi-asserted-by":"crossref","first-page":"e59787","DOI":"10.1371\/journal.pone.0059787","volume":"8","author":"UM Parikh","year":"2013","unstructured":"Parikh UM, Kiepiela P, Ganesh S, Gomez K, Horn S, Eskay K, et al. Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). PLoS One. 2013;8(4):e59787.","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"1738_CR41","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/QAD.0000000000000082","volume":"28","author":"V Cambiano","year":"2014","unstructured":"Cambiano V, Bertagnolio S, Jordan MR, Pillay D, Perriens JH, Venter F, et al. Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. AIDS. 2014;28 Suppl 1:S15\u201323.","journal-title":"AIDS"},{"issue":"5","key":"1738_CR42","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JVI.02006-06","volume":"81","author":"M Westby","year":"2007","unstructured":"Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol. 2007;81(5):2359\u201371.","journal-title":"J Virol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-015-1738-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-015-1738-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-015-1738-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T21:06:51Z","timestamp":1566853611000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-015-1738-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,16]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["1738"],"URL":"https:\/\/doi.org\/10.1007\/s11095-015-1738-7","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,16]]}}}